Eric Argirios Kitas

This inventor holds 31 USPTO granted patents and 1 published patent application, plus 3 CIPO patents and 12 EPO patents. Top assignees: Hoffmann-La Roche Inc., Arrowhead Madison, Inc., Indiana University. Active years: 2002-2021.

USPTO Granted Patents = 31 (Patent Applications = 1)

% Patents Active = 38.7

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 12 (Patent Applications = 11)

Average Co-Inventor Count = 5.6

ph-index = 7

Forward Citations = 200(Granted Patents)

Location History:

Arlesheim, CH (2002 - 2007)
Baselland, CH (2015)
Aesch BL, CH (2011 - 2017)
Aasch Baselland, CH (2018)
Aesch Baselland, CH (2018)
Aesch, CH (2007 - 2020)
Basel, CH (2021)

Company Filing History:

23 out of 5,011

Hoffmann-La Roche Inc.

patents

6 out of 19

Arrowhead Madison, Inc.

Arrowhead Pharmaceuticals, Inc.

patents

5. 1 out of 20

Roche Nimblegen, Inc.

patents

where one patent can have more than one assignee

Years Active: 2002-2021

Loading Chart...

Areas of Expertise:

BACE1 Inhibitor Peptides

Dual-Site BACE1 Inhibitors

Lipidated Incretin Receptor Ligand

Small Molecule Conjugates

Galactose Cluster-Pharmacokinetic Modulator

Peptide-Based siRNA Delivery

FBPase Inhibitors

Pyridines

Aminothiazoles

Fluorescently Labeled Growth Hormone Secretagogue

Carbamic Acid Alkyl Ester Derivatives

Pyrrolidine Derivatives

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10947272 - BACE1 inhibitor peptides (2021-03-16),

2. 10683329 - Dual-site BACE1 inhibitors (2020-06-16),

3. 10428108 - Difluoroketamide derivatives (2019-10-01),

4. 10208087 - Peptides (2019-02-19),

5. 10137170 - Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides (2018-11-27),

6. 9968647 - Small molecule conjugates for intracellular delivery of biologically active compounds (2018-05-15),

7. 9868772 - Analogs of glucagon exhibiting GIP receptor activity (2018-01-16),

8. 9796756 - Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA (2017-10-24),

9. 9301990 - Small molecule conjugates for intracellular delivery of biologically active compounds (2016-04-05),

10. 9249179 - Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA (2016-02-02),

11. 9198947 - Small molecule conjugates for intracellular delivery of nucleic acids (2015-12-01),

12. 9107957 - Peptide-based in vivo siRNA delivery system (2015-08-18),

13. 9011919 - Compositions for targeted delivery of siRNA (2015-04-21),

14. 8802773 - In vivo polynucleotide delivery conjugates having enzyme sensitive linkages (2014-08-12),

15. 8501930 - Peptide-based in vivo siRNA delivery system (2013-08-06),

Title: Eric Argirios Kitas: Innovator in BACE1 Inhibitor Peptides

Introduction: Eric Argirios Kitas, based in Aesch, Switzerland, is an accomplished inventor notable for his work in the development of innovative peptides aimed at combating Alzheimer's disease and diabetes. With a remarkable portfolio consisting of 31 patents, Kitas has made significant contributions to the field of pharmaceutical sciences.

Latest Patents: Among his latest patents, Kitas has developed dual-site BACE1 inhibitor peptides. These inventions focus on dual-site BACE1 inhibitors that serve as potential therapeutic agents. The present invention pertains to their manufacture, pharmaceutical compositions, and their application as therapeutically active substances specifically targeting diseases such as Alzheimer's. One of his notable peptides is designed to bind to both the enzymatic active site and the catalytic domain of the BACE enzyme, connected by a linker to enhance its efficacy.

Career Highlights: Eric Kitas has had a distinguished career, holding positions at well-regarded companies such as Hoffmann-La Roche Inc. and Arrowhead Madison, Inc. His tenure at these institutions has allowed him to apply his innovative ideas toward the development of impactful pharmaceutical solutions.

Collaborations: Kitas has collaborated with several esteemed colleagues, including Peter Mohr and David B Rozema. These collaborations have likely fostered an environment of creativity and innovation that contributed to the success of his inventions.

Conclusion: Eric Argirios Kitas is a prominent figure in the innovation landscape, particularly in the realm of BACE1 inhibitors. His dedication to research and development, combined with his extensive patent portfolio, underscores his commitment to advancing therapeutic treatments for Alzheimer’s disease and diabetes, ultimately contributing to improved healthcare solutions.